title: Tumor-initiating potency of a novel heterocyclic amine, aminophenylnorharman in mouse colonic carcinogenesis model.
abstract: A novel heterocyclic amine, 9-(4'-aminophenyl)-9H-pyrido[3,4-b]indole (aminophenylnorharman, APNH), which is formed from nonmutagenic 9H-pyrido[3,4-b]indole (norharman) and aniline, is mutagenic to bacteria and mammalian cells and potently carcinogenic in rats. APNH is detected in human urine samples, suggesting that humans are continuously exposed to APNH. In the present study, (32)P-postlabelin analysis revealed that the levels of APNH-DNA adduct 24 hr after the treatment with APNH (1, 5 and 20 mg/kg body weight) in male ICR mice were increased in a dose-dependent manner in the colon and liver. Based on these findings, we determined the tumor-initiating potency of APNH in an inflammation-related and two-stage mouse colon carcinogenesis model. Male Crj: CD-1 (ICR) mice were given a single intragastric administration (1, 2, 5 or 10 mg/kg body weight) of APNH and subsequent 1-week oral exposure to dextran sodium sulfate (DSS, 2% in drinking water). Treatment with APNH and DSS resulted in numerous colon tumor development: the incidence and multiplicity of the tumors were the highest in the mice received 10 mg/kg body weight of APNH and followed by DSS. Development of colon tumors was dose-dependent of APNH. Seven of 9 (77.8%) colonic adenocarcinomas developed in mice treated with APNH (10 mg/kg body weight) and DSS had beta-catenin gene mutations at codons 32 and 37, being predominantly transversion. These findings indicate that APNH has an initiating activity in inflamed mouse colon and the APNH-DNA adduct formation correlates with its tumorigenic potential.
authors.affiliation: Department of Oncologic Pathology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa, Japan. h-kohno@kanazawa-med.ac.jp
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kohno
authors.forename: Yukari
authors.initials: Y
authors.lastname: Totsuka
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Yasui
authors.forename: Rikako
authors.initials: R
authors.lastname: Suzuki
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Sugie
authors.forename: Keiji
authors.initials: K
authors.lastname: Wakabayashi
authors.forename: Takuji
authors.initials: T
authors.lastname: Tanaka
mesh_terms: D000230:Adenocarcinoma / Q000139:chemically induced*; D000818:Animals; D002273:Carcinogens / Q000008:administration & dosage / Q000633:toxicity*; D003110:Colonic Neoplasms / Q000139:chemically induced*; D018736:DNA Adducts / Q000187:drug effects*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D007211:Indoles / Q000008:administration & dosage / Q000633:toxicity*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009153:Mutagens / Q000008:administration & dosage / Q000633:toxicity*; D009154:Mutation / Q000187:drug effects; D011725:Pyridines / Q000008:administration & dosage / Q000633:toxicity*; D051176:beta Catenin / Q000235:genetics
chemical_list: D002273:Carcinogens; D018736:DNA Adducts; D007211:Indoles; D009153:Mutagens; D011725:Pyridines; D051176:beta Catenin; C421010:9-(4'-aminophenyl)-9H-pyrido(3,4-b)indole